Column 1 Column 2 Column 3 Column 4 0 FY18 FY19 (Target) Comments/Assumptions 1 Revenue $878.70 $949.00 Assume 8% increase in revenue 2 Underlying EBITDA $97.60 $105.43 Assume same underlying EBITDA Margin 3 Underlying EBITDA Margin 11.11% 11.11% 4 Interest $14.20 14.19 4.7% interest rate on $302M debt. Assume no increase in further debt as cash flow from operations is enough to cover capex requirements. 5 Depreciation & Amortisation $27.90 $29 Assume slight increase in D&A. 6 Net Cash from Ops $65.6 Assume CFO is enough to cover capex ($74M capex in FY18 but will reduce to $50M). 7 Capex $70 $50 8 Profit Before Tax $62 9 Tax $19 Assume 30% (should be less than 30% in FY19) 10 NPAT $44 This has not taken into account the $10-$13M cost reduction, which will then increase the EBITDA Margin.
The news that will appear next August is: Greencross has increased profit by 112% for FY19!
- Forums
- ASX - By Stock
- GXL
- Ann: FY18 Full Year Results - Investor Presentation
Ann: FY18 Full Year Results - Investor Presentation, page-38
-
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GXL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online